Enlivex Therapeutics Ltd. (ENLV): Price and Financial Metrics

Enlivex Therapeutics Ltd. (ENLV): $1.32

0.05 (+3.94%)

POWR Rating

Component Grades








Add ENLV to Watchlist
Sign Up

Industry: Biotech




#162 of 360

in industry

ENLV Price/Volume Stats

Current price $1.32 52-week high $4.59
Prev. close $1.27 52-week low $1.15
Day low $1.30 Volume 48,007
Day high $1.37 Avg. volume 163,158
50-day MA $3.24 Dividend yield N/A
200-day MA $2.43 Market Cap 24.51M

ENLV Stock Price Chart Interactive Chart >

Enlivex Therapeutics Ltd. (ENLV) Company Bio

Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate, which is in Phase IIb clinical trial in patients with severe sepsis; that is in investigator-initiated Phase II clinical trial for the treatment of COVID-19 patients in severe and critical conditions; and which is in Phase IIa clinical trial for the prevention of Graft Versus Host Disease in allogeneic hematopoietic stem cell transplants (HSCT) patients. The company is also developing Allocetra for the prevention of complications associated with bone marrow transplantations and/or HSCT, and acute multiple organ failure. It also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor T-Cell therapy and therapies targeting T-Cell receptor therapy. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

ENLV Latest News Stream

Event/Time News Detail
Loading, please wait...

ENLV Latest Social Stream

Loading social stream, please wait...

View Full ENLV Social Stream

Latest ENLV News From Around the Web

Below are the latest news stories about ENLIVEX THERAPEUTICS LTD that investors may wish to consider to help them evaluate ENLV as an investment opportunity.

Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis

Enrollment completed in placebo-controlled, randomized, dose-finding, multi-country, multi-center Phase II sepsis studyTopline Data Expected in late Q1 2024 Nes-Ziona, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company completed enrollment of all 120 patients in its Phase II trial of Allocetra™ in patients with sepsis. The Phase II trial is a placebo-c

Yahoo | December 20, 2023

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Yahoo | December 12, 2023

MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer

YAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the appointment of Shmulik Hess, Ph.D. to the positions of Chief Operating Officer and Chief Commercial Officer effective as of December 1, 2023. Dr. Hess will lead and oversee all operational and commercial activities at MediWound. “We are delighted to welcome Shmulik, a distinguished ind

Yahoo | November 21, 2023

Enlivex to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Nes-Ziona, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will present a corporate update at the H.C. Wainwright 25th Annual Global Investment Conference, which will take place at the Lotte New York Palace Hotel in New York City, NY Sep 11-13. The presentation will take place on Sep 12, 2023, at 5:00 PM Eastern Time. A webcast of the presentation will be

Yahoo | September 7, 2023

Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19

Data published in Frontiers in Immunology show a robust safety profile and rapid resolution from ARDS and parallel resolution of inflammation markers and elevated cytokines/chemokines, as well as substantial improvements in mortality in 21 Allocetra-treated patients with COVID-19 vs. matched historical controls Nes-Ziona, Israel, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announ

Yahoo | August 2, 2023

Read More 'ENLV' Stories Here

ENLV Price Returns

1-mo -64.13%
3-mo -56.00%
6-mo 0.76%
1-year -53.52%
3-year -87.16%
5-year N/A
YTD -51.11%
2023 -31.43%
2022 -37.00%
2021 -25.86%
2020 0.46%
2019 36.22%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!